Presentation on theme: "AEs, SAEs, and EAEs – An Overview"— Presentation transcript:
1AEs, SAEs, and EAEs – An Overview MTN 020 Training
2Layers of Safety Study participants Study site staff team Clinical affairs staff at SCHARPMTN-020 Protocol Safety Review Team (PSRT)NIAID Vaccine and Prevention Data and Safety Monitoring Board (DSMB) site
3Definition: Adverse Event Any untoward medical occurrence in a clinical research participant administered an investigational product that does not necessarily have a causal relationship with the investigational product.An AE can therefore be an unfavorable or unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of an investigational product, whether or not considered related to the investigational product.ICH E6, Glossary 1.2
4Definition: Pre-Existing Condition Any medical condition, problem, sign, symptom, or finding identified as ongoing in a study participant at the time of enrollment (prior to randomization).Pre-existing conditions are not AEs.However, if a pre-existing condition worsens in severity and/or frequency after randomization, the worsened condition is an AE.
5Case 1A participant reports that she has hypertension during her baseline medical historyHas an AE occurred?NoYesNot enough information to determineNo. Hypertension was present before randomization; therefore, it is not an AE
6Case 2A participant reports a migraine headache occurring two weeks before her Month 4 visit.Has an AE occurred?NoYesNot enough information to determineNot enough information. Where would you look for more information? Ask participant and look on PRE
7Case 3A participant has a positive pregnancy test result at her Month 7 visit.Has an AE occurred?YesNoNot enough informationNo. pregnancy is not an AE
8Case 4A participant reports new vulvar erythema at her Month 10 visit. You note erythema on pelvic exam that covers approximately 30% of her vulva.Is this an AE?YesNoNot enough informationWhat if the vulvar erythema had not been seen on exam – does this change your answer?Yes, Grade 1 AE for vulvar erythema
9Definition: Reportable Adverse Event An AE that meets study protocol criteria for reporting on adverse event case report formsFor MTN 020, this means reportable on an Adverse Experience (AE) Log CRFAEs that do not meet the protocol criteria for reporting on adverse event forms will be recorded on the Grade 1 AE Log CRF (GAE Log)
10Reportable Adverse Events There are six types of AEsthat are reportable in MTN 020.Can you name them?
11Reportable AEsAll genital, genitourinary, and reproductive system AEs exceptFetal lossesAll AEs of severity Grade 2 or higherAll serious AEsAll AEs that results in permanent discontinuation of study product useAll lab test abnormalitiesAEs that meet expedited reporting requirementAny AE not covered above will go on a Grade 1 AE Log form
12AE Log or Grade 1 AE Log CRF? Grade 1 vaginal itchingGrade 3 headacheGrade 1 nauseaGrade 1 urinary tract infectionGrade 1 weakness prompting hospital admission to rule out strokeGrade 1 allergic reaction to the vaginal ringThe only AEs NOT on the AE log CRF is grade 1 nausea. This goes on GAE
13Pelvic Exam Finding AEs Describing AEsPelvic Exam Finding AEsReport any and all new abnormal findings as AEsSpecify anatomical location (e.g., vulvar, vaginal, cervical)Use finding term as it appears in FGGT or Pelvic Exam CRF, whichever is more specificFor example, do not report “genital sore.” Instead, report “vaginal ulcer.”
14Describing AEs Genital Bleeding AEs Report only bleeding that is different from baselineMay be expected (due to menses or contraceptive use) or unexpectedUse appropriate term from FGGT/SSPUse separate terms for pregnancy-related bleeding – SSP Section 10.6If bleeding associated with pelvic exam finding, report finding as the AEThe bleeding is a sign of the finding, - comment on in Comments field
15Antepartum BleedingBleeding during pregnancy prior to the onset of labor (regardless of trimester) will be graded per the table below:
16AE Severity The severity of all AEs must be graded as Grade 1 = Mild Grade 2 = ModerateGrade 3 = SevereGrade 4 = Potentially Life-ThreateningGrade 5 = DeathAssign grades based on the DAIDS Female Genital Grading Table (FGGT) and DAIDS Table for Grading Adult and Pediatric Adverse Events (Toxicity Table)See SSP Section 11.3 for tips and guidanceSeverity reflects the intensity of the AE.AEs listed in both the Tox Table and the FGGT should be graded per the FGGT.AEs not listed in the FGGT should be graded per the Tox Table.AEs not listed in the FGGT or the Tox Table should be graded per the “estimating severity grade row” on page 1 of the Tox Table.
17Severity Grading of Vaginal Candidiasis Normal = absence of symptoms regardless of candida test resultsGrade 1 = positive wet mount or other laboratory test for yeast, with mild symptomsGrade 2 = positive wet mount or other laboratory test for yeast, with moderate to severe symptomsGrade 3: Not applicableGrade 4: Not applicableThis slide is included because questions often arise on how to deal with symptomatic and asymptomatic yeast. See FGGT for a guide.
18Relationship to Study Product The relationship of each AE to study product must be assessed as:RelatedNot Related
19Factors to ConsiderPre-clinical and clinical profile of the study products: protocol, package inserts, investigators brochures, other published informationTiming of product use relative to onset, resolution, and/or recurrence of the AELikelihood of observing the AE in the study population in the absence of product usePresence of other conditions or exposures that could have caused the AEClinical judgment, including judgment of biologic plausibilityIf not related, specify reason you made this judgement on line provided (not in Comments)
20AE OutcomeAll AEs – reportable and not reportable – must be followed clinically until the AE resolves or stabilizesResolution = return to baseline severity gradeStabilization = persistence at a severity grade above baseline for 3 consecutive monthly evaluations
21AE OutcomeAt each visit, an authorized study clinician should review all previously reported ongoing AEs to evaluate their current statusOftentimes the outcome of an AE will not be available when the AE is first documentedIn such cases, documentation should be updated when the final outcome becomes available
22AE OutcomeIf an AE increases in severity or frequency, the higher grade AE must be documented (and reported) as a new AEIf an AE completely resolves and then recurs at a later date, the second occurrence must be documented (and reported) as a new AE
23Definition: Serious Adverse Event Any untoward medical occurrence that at any dose:Results in deathIs life-threateningRequires inpatient hospitalization or prolongation of existing hospitalizationResults in persistent or significant disability/ incapacityIs a congenital anomaly/birth defectImportant medical events that may not be immediately life-threatening or result in death or hospitalization, but may jeopardize the participant or may require intervention to prevent one of the above-listed outcomes, also may be considered serious.
24Seriousness of Adverse Events Seriousness ≠ severitySAEs are a subset of all AEsAll SAEs are reportable on AE Log formsAll AEs must be assessed by authorized study staff to determine whether they meet the definition of serious source document and record on AE Log formSeriousness is based on the outcome or action associated with an AE, whereas severity reflects the intensity of the AE
25Expedited Adverse Event AE that meets criteria in the study protocol for additional reporting for rapid review and assessment by DAIDSReporting period begins once the participant is randomized and continues through the final study visit (Study Exit/Termination Visit)Only suspected, unexpected serious adverse reactions (SUSARs) as defined in Version 2.0 of the EAE Manual will be reported to DAIDS NEED TO CHECK ABOVE
26Let’s Discuss More Adverse Events Suppose a participant has a grade 3 decreased hemoglobin at her semi-annual visitIs this an adverse event?YesNoNot enough information to determineYes.Follow-up: Is it reportable? (Yes)
27Let’s Discuss More Adverse Events Suppose a participant has a grade 4 decreased hemoglobin at her semi-annual visitIs this serious?YesNoNot enough information to determineAlthough most Grade 4 events fall into a category of “potentially life threatening” on DAIDS, they are NOT necessarily considered serious events.
28Let’s Discuss Adverse Events Suppose a participant has an argument with her partner related to her participation in the study. She was late meeting him because a study visit took longer than expected. He thinks the study is taking up too much of her time and he does not want to hear any more from her about safe sex and using condoms. The argument escalates and he pushes her to the floor, resulting in a laceration on her forehead and a broken collarbone. She is treated in the emergency department and then admitted to the hospital for observation related to her head injury.How many AEs have occurred?Two AEs have occurred: laceration on forehead and broken collarboneFollow-up: Are they both serious? (Based on the description given, only the laceration is serious, because it resulted in hospitalization.)OneTwoNone
29Let’s Discuss Adverse Events Suppose a participant has an argument with her partner related to her participation in the study. She was late meeting him because a study visit took longer than expected. He thinks the study is taking up too much of her time and he does not want to hear any more from her about safe sex and using condoms. The argument escalates and he pushes her to the floor, resulting in a laceration on her forehead and a broken collarbone. She is treated in the emergency department and then admitted to the hospital for observation related to her head injury.How many AEs are EAEs?Yes – Laceration is EAE.OneTwoNone
30Let’s Discuss Adverse Events Suppose a participant has a positive pregnancy test at her Month 6 visit. At her Month 7 visit, her pregnancy test is negative. She reports having no symptoms between visits and is surprised that she is no longer pregnant.Is this an adverse event?YesNoNot enough information to determineFetal losses are not considered AEs (therefore no AE, no reportable AE, no SAE)
31A Few Extra Reporting Tips Only symptomatic BV confirmed by wet mount should be reported as an AEOnly report symptomatic candida infections confirmed by wet mount should be reported as an AEChlamydia should be “genitourinary chlamydia infection”Gonorrhea should be “genitourinary gonorrhea infection”Suspected herpes lesions should be captured as “ulcers”